Image via Endpoints News
Last updated
UCB: Ma Activity
UCB acquiring Neurona Therapeutics for $650M plus up to $500M in milestones to expand epilepsy portfolio
Source: Endpoints News
The leadership read
Consolidation shifts the leadership question from growth to integration. For UCB in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Oceania, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Backdrop: a 104.6 (Hot) Talent Market Index (down 1.9 on the month) with Oceania activity steady (+1.1pts).
UCB: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's EMEA signal flow; 4 tracked across 80 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
Ma Activity · Oceania
Teva Pharmaceuticals →Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Ma Activity · Americas
Biogen →Biogen is relying on drugs acquired through the Apellis deal to offset weak sales of Leqembi (Alzheimer's drug), indicating strategic dependence on M&A to bolster pipeline performance.
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Intelligence powered by Autonodal ↗